# Clinical Study To Evaluate The Performance And Safety Of Favipiravir in COVID-19

> **NCT04336904** · PHASE3 · UNKNOWN · sponsor: **Giuliano Rizzardini** · enrollment: 100 (estimated)

## Conditions studied

- COVID-19

## Interventions

- **DRUG:** Favipiravir
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT04336904
- **Lead sponsor:** Giuliano Rizzardini
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-03-25
- **Primary completion:** 2020-07
- **Final completion:** 2020-07
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2020-04-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04336904

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04336904, "Clinical Study To Evaluate The Performance And Safety Of Favipiravir in COVID-19". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT04336904. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*